Rightway $155M Series E: $1.75B Valuation and an IPO Horizon

What happened

Rightway, a New York-based pharmacy benefit manager (PBM) and care navigation company, has closed a $155 million Series E. Francisco Partners led the round, with Thrive Capital and Khosla Ventures participating.1 The deal was dated September 24, 2026, and Thrive and Khosla are existing backers rather than new entrants.3

The company's own announcement focused on the business. It said the money will expand its AI capabilities and the technology behind its pharmacy benefits model, and it cited 45 Fortune 500 companies as clients.1 The bigger financial details came from separate reporting. According to a person with direct knowledge, the financing set Rightway's valuation at $1.75 billion. The company says it has raised $281 million in total and is considering an IPO within the next four years.2 That report also describes Rightway as profitable and serving about 3 million people.2

The pitch: a PBM that says it doesn't profit from drug prices

Rightway's argument is mainly about how it gets paid. Feldman, speaking for the company, said its only revenue stream is a per-enrollee fee that has no connection to drug prices. He argued that this structure lowers total pharmacy spending for clients and slows how fast those costs grow.2 The company also says its model caps total pharmacy spend and prices GLP-1 drugs and rare, high-cost medications at net cost.1

This approach answers a common complaint about traditional PBMs. Critics say intermediaries can earn more when list prices rise, through rebates and spread pricing. Employers who pay for workforce drug coverage have pushed for clearer accountability on where that money goes.1 A flat per-member fee is a simple counter-offer: if Rightway's income doesn't change with drug prices, the company has less reason to favor expensive drugs.

The mention of GLP-1s is notable. Weight-loss and diabetes drugs in that class have become one of the most expensive line items for employer health plans. A vendor promising net-cost pricing and a cap on total spend is targeting what may be the most pressing concern for benefits buyers today.

How the stories differ

The three accounts agree on the core facts: the amount, the series, the lead investor, and the participants.123 They differ in emphasis. The company-facing coverage frames the raise around employer demand for transparency and AI investment, and it does not mention valuation or IPO plans.1 The $1.75 billion figure and the IPO timeline come from a single source with direct knowledge, not from an official disclosure.2 Readers should treat the valuation as credible but unconfirmed.

The four-year IPO window is also loose. "Weighing an IPO" within that period signals intent and may help with recruiting and positioning. It is not a filing plan. Profitability gives Rightway more control over timing than many venture-backed health tech companies have, but public-market conditions will decide the actual date.

The broader funding picture

Rightway's raise is part of a busy month for health tech financing focused on medications and payers. Earlier in September, Forus, an AI-powered medication access platform, raised a $150 million Series C led by Bain Capital Ventures, with Thrive Capital among the existing investors. That round reportedly valued Forus at $3 billion, only four months after a $160 million Series B.3 Penelope Health, which builds real-time payer policy intelligence, secured a $100 million commitment alongside a partnership with Thoreau.3 Basalt Health raised $20 million to extend its AI platform into discharge planning and payer workflows.3

Thrive Capital appears in both the Rightway and Forus rounds.3 This suggests some investors are betting broadly on the pharmacy and medication-access layer of healthcare. The common theme is that the money is going to companies that sit between payers, providers, and drug spending, often with AI positioned as the operating advantage.

Our read

The AI angle is the headline, but Rightway's real advantage appears to be its business model, not its software. AI-driven efficiency is easy to claim and hard to verify. A fee structure that separates revenue from drug prices is a structural difference that employers can understand and auditors can check. Combined with reported profitability and an established Fortune 500 client base, it gives Rightway a clearer story for public markets than many of its peers.

The open question is scale. Rightway serves about 3 million people2, which is small next to the incumbent PBMs that dominate the market. A $1.75 billion valuation implies investors expect transparency to become a buying requirement rather than a niche preference. If employer pressure on drug costs, especially for GLP-1s, keeps rising, that bet looks reasonable. If incumbents adopt similar pricing terms, Rightway's main differentiator could become harder to defend before it reaches the public markets.